Somewhat Positive News Coverage Somewhat Unlikely to Affect Grifols SA, Barcelona (GRFS) Stock Price

Media coverage about Grifols SA, Barcelona (NASDAQ:GRFS) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Grifols SA, Barcelona earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.9599684506404 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

These are some of the news articles that may have impacted Accern’s analysis:

Shares of Grifols SA, Barcelona (GRFS) traded up $0.23 during mid-day trading on Thursday, reaching $22.18. 283,080 shares of the company’s stock were exchanged, compared to its average volume of 619,167. The firm has a market capitalization of $5,740.00, a PE ratio of 20.45, a price-to-earnings-growth ratio of 1.66 and a beta of 1.02. The company has a current ratio of 3.17, a quick ratio of 1.39 and a debt-to-equity ratio of 1.69. Grifols SA, Barcelona has a 1 year low of $15.47 and a 1 year high of $24.20.

Several equities research analysts recently issued reports on the stock. UBS cut shares of Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research report on Friday, November 24th. Citigroup assumed coverage on shares of Grifols SA, Barcelona in a research report on Tuesday, October 31st. They issued a “buy” rating on the stock. BidaskClub raised shares of Grifols SA, Barcelona from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Finally, Zacks Investment Research cut shares of Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Grifols SA, Barcelona presently has a consensus rating of “Hold” and an average target price of $24.00.

TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Grifols SA, Barcelona (GRFS) Stock Price” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at

About Grifols SA, Barcelona

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Insider Buying and Selling by Quarter for Grifols SA, Barcelona (NASDAQ:GRFS)

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit